Hernández-Valencia M, Basurto L, Saucedo R, Vargas C, Ruiz M, García E, Galván RE, León S, Salazar L, Zárate A

Language: Spanish
References: 14
Page: 149-153
PDF size: 100.57 Kb.

ABSTRACT

Introduction: Menopause is determined by descent in serum levels, that produces atrophy tissues and is done manifests clinically by postmenopausal symptoms. At present options for estrogens administration exist but these ways have different bio-disponibility, the object of this study was compared the effect of hormonal replacement therapy (HRT) by oral and intranasal way on changes in postmenopausal symptoms. Material and methods: Two groups of study were formed, the group I received estrogens by intranasal route (300 µg), the group II received estrogens by oral route (0.625 mg), with daily dose at night during 6 months. To appraisal efficacy of the HRT was used Greene scale, and was applied in each patient before the hormonal intervention and later each month during follow-up study. Results: Scores from Greene scale showed changes in first month of HRT in both groups, but the statistical differences could be observed until the third months, upon considering each one of the five components of the scale, which vasomotor, sexual and somatic component were significantly different (p ‹ 0.05). Pharmacological response was evaluated for gonadotropins concentrations that had significant descent (p ‹ 0.05), with LH 32.6 ± 4.2 to 12.2 ± 3.1 mUI/mL and FSH 81.6 ± 9.4 to 26.4 ± 6.3 mUI/mL, as well as increment in estradiol 10.8 ± 2.4 to 94.7 ± 8.6 pg/mL after use of TRH. Discussion: The Greene scale permitted to evaluate the therapeutic equivalence with estrogens among the nasal and oral route on postmenopausal symptoms, and was observed that somatic, vasomotor and sexual components have a similar response with the two routes, since have same profile of symptoms descent, although with greater scores with the oral way. Both route have shown a clinical benefic effect for postmenopausal symptoms control.

REFERENCES

1. Grady D. Postmenopausal hormones therapy for symptoms only. N Engl J Med 2003; 348: 19-21.

2. Zárate A, Saucedo R, Hernández-Valencia M. El lugar de la terapia de reemplazo hormonal para la mujer menopáusica en la actualidad. Acta Med Grupo Ángeles 2004; 2: 129-130.

3. Greendale G, Reboussin B, Hogan P. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998; 92: 982-988.

4. Zárate A, Hernández-Valencia M, Basurto L. Estado actual del tratamiento hormonal en la menopausia. Rev Fac Med UNAM 2005; 48: 14-17.

5. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J. Biological effects of estradiol-17b in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-541.

6. O’Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35: 18-24.

7. Lievertz R. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987; 156: 1289-1293.

8. Studd JW, Pornel B, Marton I. Dose-response study of the efficacy and acceptability of intranasal 17-b estradiol for menopausal symptoms. Lancet 1999; 353: 1574-1578.

9. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzalez P, Vijod MA, Lobo RA. A randomized comparison of monoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988; 159: 1540-1546.

10. Hernández-Valencia M, Ángeles L, Saucedo R, Mora C, Zárate A. Efectividad del estradiol por vía nasal como terapia de reemplazo hormonal. Acta Med Grupo Ángeles 2003; 1: 77-80.

11. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-461.

12. Jick H, Derby JH, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996; 348: 981-985.

13. Greene JG. Constructing a standard climacteric scale. Maturitas 1988; 29: 25-31.

14. Greene JG. A factor analytic study of climacteric symptoms. J Psychosom Res 1976; 20: 425-430.